Yew Bio-Pharm Chairman & CEO Issues Letter to Shareholders
HARBIN, China, Jan. 23, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders:
DEAR FELLOW SHAREHOLDERS:
With the arrival of the Chinese New Year, I would like to take this opportunity to express my appreciation to all shareholders for the trust and support offered to Yew Bio-Pharm and myself. With all the hard work and determination from employees and management, we achieved solid revenue growth for each of our business segments over the past three years.
2013 was a milestone year for Yew Bio-Pharm as our common stock began trading on the U.S. OTCBB market, resulting in greater recognition from the industry. We are also making progress financially, with total revenue up nearly 13% to $5.45 million for the first nine months, compared with the same period last year as a result of a solid start at the beginning of the year.
To summarize our results for the 2013 third-quarter:
Total revenue rose 12.5% to $1.54 million from $1.37 million for the 2012 third quarter;
Sale of TCM raw materials was $1.00 million; sale of yew trees was $0.45 million; and sale of handicrafts was 0.09 million, representing increases of 12.5%, 13.2% and 0.09% from the year-ago quarter, respectively;
Operating profit was $0.91 million, compared with $1.14 million in the year-ago quarter; and
Net income was $0.77 million, or $0.01 per diluted share, compared with $0.82 million, or $0.02 per diluted share, in 2012 third quarter.
Three Months Ended September 30,
Nine Months Ended September 30,
Revenues:
2013
2012
2013
2012
TCM Raw Materials
$1,005,323
$893,909
$3,171,814
$2,860,552
Yew Trees
448,810
396,416
2,102,417
1,853,504
Handicrafts
90,194
82,699
175,402
118,734
Total Revenues
$1,544,327
$1,373,024
$5,449,633
$4,832,790
Looking ahead to the New Year, I am both excited about our growth strategy and confident about our ability to achieve further success. I am extremely pleased with our first-class leadership team, operational strength, fiscal discipline, and the value we continue to provide to our customers, partners, employees, and shareholders.
On behalf of the Yew Bio-Pharm Group, I would like to wish you and your families a Happy Chinese New Year! We're just getting started.
Sincerely,
Zhiguo Wang
Chairman & Chief Executive Officer
ABOUT YEW BIO-PHARM GROUP, INC
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit www.yewchina.com
Investor Relations Contacts:
Judy Lin Sfetcu | Matt Sheldon
PondelWilkinson Inc.
Tel: 310-269-5980
E-mail: investor@pondel.com
SOURCE Yew Bio-Pharm Group, Inc.
Copyright 2014 PR Newswire
HARBIN, China, Jan. 23, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders:
DEAR FELLOW SHAREHOLDERS:
With the arrival of the Chinese New Year, I would like to take this opportunity to express my appreciation to all shareholders for the trust and support offered to Yew Bio-Pharm and myself. With all the hard work and determination from employees and management, we achieved solid revenue growth for each of our business segments over the past three years.
2013 was a milestone year for Yew Bio-Pharm as our common stock began trading on the U.S. OTCBB market, resulting in greater recognition from the industry. We are also making progress financially, with total revenue up nearly 13% to $5.45 million for the first nine months, compared with the same period last year as a result of a solid start at the beginning of the year.
To summarize our results for the 2013 third-quarter:
Total revenue rose 12.5% to $1.54 million from $1.37 million for the 2012 third quarter;
Sale of TCM raw materials was $1.00 million; sale of yew trees was $0.45 million; and sale of handicrafts was 0.09 million, representing increases of 12.5%, 13.2% and 0.09% from the year-ago quarter, respectively;
Operating profit was $0.91 million, compared with $1.14 million in the year-ago quarter; and
Net income was $0.77 million, or $0.01 per diluted share, compared with $0.82 million, or $0.02 per diluted share, in 2012 third quarter.
Three Months Ended September 30,
Nine Months Ended September 30,
Revenues:
2013
2012
2013
2012
TCM Raw Materials
$1,005,323
$893,909
$3,171,814
$2,860,552
Yew Trees
448,810
396,416
2,102,417
1,853,504
Handicrafts
90,194
82,699
175,402
118,734
Total Revenues
$1,544,327
$1,373,024
$5,449,633
$4,832,790
Looking ahead to the New Year, I am both excited about our growth strategy and confident about our ability to achieve further success. I am extremely pleased with our first-class leadership team, operational strength, fiscal discipline, and the value we continue to provide to our customers, partners, employees, and shareholders.
On behalf of the Yew Bio-Pharm Group, I would like to wish you and your families a Happy Chinese New Year! We're just getting started.
Sincerely,
Zhiguo Wang
Chairman & Chief Executive Officer
ABOUT YEW BIO-PHARM GROUP, INC
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit www.yewchina.com
Investor Relations Contacts:
Judy Lin Sfetcu | Matt Sheldon
PondelWilkinson Inc.
Tel: 310-269-5980
E-mail: investor@pondel.com
SOURCE Yew Bio-Pharm Group, Inc.
Copyright 2014 PR Newswire
